<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529450</url>
  </required_header>
  <id_info>
    <org_study_id>SKIN0009</org_study_id>
    <secondary_id>SU-09022011-8371</secondary_id>
    <secondary_id>21759</secondary_id>
    <nct_id>NCT01529450</nct_id>
  </id_info>
  <brief_title>Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors</brief_title>
  <official_title>A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single-center, open label, pilot study to investigate the safety and
      efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.

      Primary Objectives:

      • To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals
      with locally advanced or metastatic BCC who have been previously treated with a non-LDE225
      Smo inhibitor.

      Secondary Objectives:

        -  To evaluate the effect of oral LDE225 on tumor tissue biomarkers of BCC activation (Gii
           1, 2, Patched 1,2 and Ki67) in individuals which are non-na&quot;ive to Smo inhibitors other
           than LDE225, at baseline and at end-of-treatment

        -  To describe adverse effects of oral LDE225 in individuals with a history of non-LDE225
           Smo inhibitor usage

        -  To assess the overall survival rates of individuals with locally advanced BCC or
           metastatic BCC who have previously taken a non-LDE225 Smo inhibitor after treatment with
           LDE225
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective single-center, open label, pilot study to investigate the safety and
      efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.

      Primary Objectives:

      • To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals
      with locally advanced or metastatic BCC who have been previously treated with a non-LDE225
      Smo inhibitor.

      Secondary Objectives:

        -  To evaluate the effect of oral LDE225 on tumor tissue biomarkers of BCC activation (e.g.
           Gli and Ki67) in individuals which are non-naive to Smo inhibitors other than LDE225, at
           baseline and at end-of-treatment

        -  To describe adverse effects of oral LDE225 in individuals with a history of non-LDE225
           Smo inhibitor usage
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) of All Participants</measure>
    <time_frame>End of treatment or at time of disease progression (up to 58 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular Markers Associated With Clinical Response</measure>
    <time_frame>Assessed on day 1</time_frame>
    <description>Following consent, historical biopsy samples were analyzed for molecular markers associated with clinical response. Tumors were analyzed and present of Smooth mutation (SMO [genetic changes which influence Ki 67 and Gli levels]). was determined. The number of participants with and without SMO were reported by clinical outcome (SD = stable disease; PD = progressive disease).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Refractory Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients previously treated with non-LDE225 Smo inhibitor who were refractory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistance Developed Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225</intervention_name>
    <description>800-mg (4 200-mg capsules/day) capsule</description>
    <arm_group_label>Refractory Group</arm_group_label>
    <arm_group_label>Resistance Developed Group</arm_group_label>
    <other_name>NVP-LDE225</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older.

          2. Histologically documented diagnosis of basal cell carcinoma deemed to be locally
             advanced or metastatic who have previously received a non-LDE225 Smo inhibitor.

          3. World Health Organization (WHO) performance status &lt;= 2

          4. At least one measurable site of disease (as defined by Response Evaluation Criteria in
             Solid Tumors), or other disease specific response assessment criteria, as appropriate.
             State age restriction and/or gender/race-ethnic restrictions.

          5. Patients with adequate bone marrow, liver and renal function, as specified below:

               -  Absolute Neutrophil Count (ANC) &gt;= 1.5 x 10^9/L

               -  Hemoglobin (Hgb) &gt;= 9 g/dL

               -  Platelets &gt;= 80 x 10^9/L

               -  Serum total bilirubin &lt;= 1.5 x upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;= 2.5 x ULN
                  or &lt;= 5 x ULN if liver metastases are present

               -  Plasma creatine phosphokinase (CK) &lt; 1.5 x ULN

               -  Serum creatinine &lt;= 1.5 x ULN or 24-hour clearance &gt;= 50ml/min

          6. Written informed consent obtained prior to any screening procedures

        Exclusion Criteria:

          1. Patients who have had major surgery within 4 weeks of initiation of study medication.

          2. Patients with concurrent uncontrolled medical conditions that may interfere with their
             participation in the study or potentially affect the interpretation of the study data.

             State restrictions regarding use of other Investigational Agents.

          3. Patients unable to take oral drugs or with lack of physical integrity of the upper
             gastrointestinal tract or known malabsorption syndromes.

             State exclusion requirements due to co-morbid disease or incurrent illness, as needed.

          4. Patients who have previously been treated with systemic LDE225.

          5. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular
             dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on
             concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as
             3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) inhibitors (statins), clofibrate and
             gemfibrozil, and that cannot be discontinued at least 2 weeks prior to starting LDE225
             treatment. If it is essential that the patient stays on a statin to control
             hyperlipidemia, only pravastatin may be used with extra caution.

             b) Patients who are planning on embarking on a new strenuous exercise regimen after
             initiation of study treatment. Note: Muscular activities, such as strenuous exercise,
             that can result in significant increases in plasma CK levels should be avoided whilst
             on LDE225 treatment.

          6. Patients who have taken part in an experimental drug study within 4 weeks of
             initiating treatment with LDE225.

          7. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted
             therapy or radiotherapy) concurrently or within 2 weeks of starting treatment with
             LDE225.

          8. Patients who are receiving treatment with medications known to be moderate and strong
             inhibitors or inducers of cytochrome (CYP)3A4/5 or drugs metabolized by CYP2B6 or
             CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before
             starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should
             be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior
             to starting treatment with LDE225.

          9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test (&gt; 5 mIU/mL).

        10 Women of child-bearing potential, defined as all women physiologically capable of
        becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes
        intercourse with a male partner and women whose partners have been sterilized by vasectomy
        or other means, UNLESS they are using two birth control methods. The two methods can be a
        double barrier method or a barrier method plus a hormonal method. Adequate barrier methods
        of contraception include:

          -  Diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge
             or spermicide. Hormonal contraceptives include any marketed contraceptive agent that
             includes an estrogen and/or a progestational agent.

          -  Reliable contraception should be maintained throughout the study and for 3 months
             after study drug discontinuation.

             11 Patients unwilling or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Danial C, Sarin KY, Oro AE, Chang AL. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res. 2016 Mar 15;22(6):1325-9. doi: 10.1158/1078-0432.CCR-15-1588. Epub 2015 Nov 6.</citation>
    <PMID>26546616</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <results_first_submitted>March 11, 2016</results_first_submitted>
  <results_first_submitted_qc>September 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2016</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anne Chang</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>basal cell carcinoma, sonidegib, smoothened inhibitor, hedgehog</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Refractory Group</title>
          <description>Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
        </group>
        <group group_id="P2">
          <title>Resistance Developed Group</title>
          <description>Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants with evaluable data are included for Baseline Characteristics</population>
      <group_list>
        <group group_id="B1">
          <title>Refractory Group</title>
          <description>Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
        </group>
        <group group_id="B2">
          <title>Resistance Developed Group</title>
          <description>Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="24"/>
                    <measurement group_id="B2" value="54" spread="9"/>
                    <measurement group_id="B3" value="57" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Size of disease by RECIST criteria</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="1.3"/>
                    <measurement group_id="B2" value="4.2" spread="2.4"/>
                    <measurement group_id="B3" value="4.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) of All Participants</title>
        <time_frame>End of treatment or at time of disease progression (up to 58 weeks)</time_frame>
        <population>Progression is defined using RECIST version 1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion or the appearance of new lesion.</population>
        <group_list>
          <group group_id="O1">
            <title>Refractory Group</title>
            <description>Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
          </group>
          <group group_id="O2">
            <title>Resistance Developed Group</title>
            <description>Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) of All Participants</title>
          <population>Progression is defined using RECIST version 1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion or the appearance of new lesion.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="12"/>
                    <measurement group_id="O2" value="36" lower_limit="14" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Molecular Markers Associated With Clinical Response</title>
        <description>Following consent, historical biopsy samples were analyzed for molecular markers associated with clinical response. Tumors were analyzed and present of Smooth mutation (SMO [genetic changes which influence Ki 67 and Gli levels]). was determined. The number of participants with and without SMO were reported by clinical outcome (SD = stable disease; PD = progressive disease).</description>
        <time_frame>Assessed on day 1</time_frame>
        <population>Participants with tissue available for screening were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants received LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Molecular Markers Associated With Clinical Response</title>
          <description>Following consent, historical biopsy samples were analyzed for molecular markers associated with clinical response. Tumors were analyzed and present of Smooth mutation (SMO [genetic changes which influence Ki 67 and Gli levels]). was determined. The number of participants with and without SMO were reported by clinical outcome (SD = stable disease; PD = progressive disease).</description>
          <population>Participants with tissue available for screening were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SMO Present (outcome SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMO absent (outcome SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMO Present (outcome PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMO absent (outcome PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants with evaluable data are included for Adverse Events</desc>
      <group_list>
        <group group_id="E1">
          <title>Refractory Group</title>
          <description>Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
        </group>
        <group group_id="E2">
          <title>Resistance Developed Group</title>
          <description>Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
LDE225: 800-mg (4 200-mg capsules/day) capsule</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.3)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.3)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear canal stenosis</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ear drainage</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>hearing loss</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>appetite decrease</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>taste disturbance</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>vomit</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>candidiasis</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ecchymosis</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>laceration</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>elevated creatine kinase</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hip fracture</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>muscle cramps</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>restless arms and legs</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>rhabdomyolysis</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>neoplasm</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>altered mental status</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>agitation</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Chang, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 721 7151</phone>
      <email>alschang@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

